Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
Damiana Scuteri, Paolo Tonin, Pierluigi Nicotera...
https://pubmed.ncbi.nlm.nih.gov/36006191/Actively Recruiting
Led by Oslo University Hospital · Updated on 2025-06-27
450
Participants Needed
6
Research Sites
12 weeks
Total Duration
Researchers are evaluating treatments for chronic migraine, a condition marked by 15 or more headache days per month for over three months, with at least eight days featuring migraine symptoms. This trial aims to assess the effectiveness of combining onabotulinumtoxin A with CGRP monoclonal antibody therapy compared to CGRP therapy alone in preventing chronic migraine attacks. The study also monitors side effects and changes in disease activity, involving about 450 participants in Norway aged 18 to 70 years. Participants will all receive monthly CGRP monoclonal antibody injections as background treatment. They will be randomly assigned to receive either onabotulinumtoxin A injections 155 units at 31 muscle sites or placebo injections following a modified PREEMPT protocol. The treatment period lasts 12 weeks. Before starting treatment, participants will record headache data using an electronic diary app for at least four weeks. The study includes three in-person visits and three telephone visits across a total of 20 weeks. During the study, participants keep detailed headache diaries to track frequency, intensity, medication use, and headache type. Telephone follow-ups at weeks 4 and 8 review treatment adherence and safety. After 12 weeks of treatment, a clinical visit assesses study outcomes, including changes in monthly migraine days and headache severity. Participants continue diary entries for an additional four weeks until the final telephone visit, marking the studys end. The primary outcome is the reduction in monthly migraine days over 12 weeks.
CONDITIONS
The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy
A
Anne Hege Aamodt, Prof, MD, PhD
B
Burcu Bezgal, Neurologist PhD student
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Oslo University Hospital
Lead Sponsor
St. Olavs Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for inclusion and consent
Duration - Minimum 4 weeks
Participants register headache data daily in an electronic diary before starting the study treatment.
1 baseline visit (in-person) followed by daily electronic diary entries
Duration - 12 weeks
Participants receive monthly injections of CGRP monoclonal antibodies and either onabotulinumtoxin A or placebo injections according to the study group for migraine prevention.
3 in-person visits and 2 telephone visits for medication administration and follow-up
Duration - 4 weeks
Participants continue headache diary entries and have a final telephone visit to conclude the study assessments.
1 telephone visit
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Damiana Scuteri, Paolo Tonin, Pierluigi Nicotera...
https://pubmed.ncbi.nlm.nih.gov/36006191/Maya T Gerstein, R J Wirth, Alyssa A Uzumcu...
https://pubmed.ncbi.nlm.nih.gov/36905166/S K Aurora, D W Dodick, H-C Diener...
https://pubmed.ncbi.nlm.nih.gov/24107267/Stewart Tepper, Messoud Ashina, Uwe Reuter...
https://pubmed.ncbi.nlm.nih.gov/28460892/Laszlo Mechtler, Nicolas Saikali, Jennifer McVige...
https://pubmed.ncbi.nlm.nih.gov/35069416/Cristina Tassorelli, Hans-Christoph Diener, David W Dodick...
https://pubmed.ncbi.nlm.nih.gov/29504482/H C Diener, D W Dodick, S K Aurora...
https://pubmed.ncbi.nlm.nih.gov/20647171/Hans-Christoph Diener, Cristina Tassorelli, David W Dodick...
https://pubmed.ncbi.nlm.nih.gov/30806518/Simona Sacco, Faisal Mohammad Amin, Messoud Ashina...
https://pubmed.ncbi.nlm.nih.gov/35690723/Richard B Lipton, Peter J Goadsby, Jeff Smith...
https://pubmed.ncbi.nlm.nih.gov/32209650/Oslo University Hospital
Lead Sponsor
St. Olavs Hospital
Collaborating Sponsor